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Abstract: Because plants are estimated to produce over 200,000 metabolites, research into 
new natural substances that can be used in the pharmaceutical, agrochemical and  
agro-industrial production of drugs, biopesticides and food additives has grown in recent 
years. The global market for plant-derived drugs over the last decade has been estimated to 
be approximately 30.69 billion USD. A relevant specific example of a plant that is very 
interesting for its numerous pharmacological properties, which include antidiabetic, 
anticarcinogenic, and neuroprotective effects is Gymnema sylvestre, used as a medicinal 
plant in Asia for thousands of years. Its properties are attributed to triterpenoidic saponins. 
In light of the considerable interest generated in the chemistry and pharmacological 
properties of G. sylvestre triterpenes and their analogues, we have undertaken this  
review in an effort to summarise the available literature on these promising bioactive 
natural products. The review will detail studies on the isolation, chemistry and bioactivity 
of the triterpenoids, which are presented in the tables. In particular the triterpenoids  
oxidised at C-23; their isolation, distribution in different parts of the plant, and their  
NMR spectral data; their names and physico-chemical characterisation; and the  
biological properties associated with these compounds, with a focus on their potential 
chemotherapeutic applications. 
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1. Introduction: Medicinal Plants and Their Secondary Metabolites 
Plants form an important part of our diet, and plant constituents and their nutritional value have 
been intensively studied for decades. In addition to primary metabolites (carbohydrates, lipids and 
amino acids), plants are able to synthesise a wide variety of compounds referred to as secondary 
metabolites. These are defined as compounds that do not have a well-recognised role in the essential 
processes of the plant but play an important role in the interactions of the plant with the environment [1]. 
Despite the term “secondary”, these compounds confer selective advantages to plant species by 
suppressing the growth of weeds; providing protection from predators, pathogens and abiotic stress; 
attracting pollinators, providing benefits with respect to animals and microorganisms; and serving as 
signals in interactions with other plants [2–8]. In addition, they play a role at the cellular level as 
growth regulators, modulators of gene expression and signal transducers [9]. Because plants are 
estimated to produce over 200,000 metabolites [10], research into new natural substances that can be 
used in the pharmaceutical, agrochemical and agro-industrial production of drugs, biopesticides, and 
food additives has grown in recent years. The yield of these compounds is often low (less than 1% dry 
weight) and depends greatly on the physiological and developmental stage of the plant [11]. Of the 
more than 400,000 species of plants, the phytochemicals of only a small percentage have been studied, 
and of these phytochemicals, only a small percentage has been examined for their biological properties 
because this research is complex and expensive. Two-thirds of medicinal plants are collected from the 
wild, but in Europe, only approximately 10% of plants used for commercial purposes are cultivated [12]. 
Currently one fourth of all prescribed pharmaceuticals in industrialised countries contains compounds 
that are directly or indirectly, via semi-synthesis, derived from plants. Furthermore, 11% of the  
252 drugs considered as basic and essential by WHO are exclusively derived from flowering  
plants [13]. The global market for plant-derived drugs has been estimated to be approximately 30.69 
billion USD annually over the last decade, and phytochemicals such as terpenes and steroids represent 
the most significant fraction with estimated annual sales of 12.4 billion USD [14]. 
Higher plants are rich source of bioactive constituents or phyto-pharmaceuticals used in the 
pharmaceutical industry. Many of these pharmaceuticals are still in use today, and often, useful 
synthetic substitutes have been found that possess the same efficacy and pharmacological specificity [15]. 
In addition to the field of pharmacology, secondary metabolites from plant extracts can also be used in 
the agrochemical sector. The recent interest in chemical to be used as defences for agricultural crops 
with less impact on the environment from operators in the sector and consumers has stimulated 
research into the isolation of new molecules of natural origin for use as biopesticides [9]. 
Over 60% of cancer drugs and 66% of antimicrobial compounds on the market today (including 
antibacterial, antifungal and antiviral compounds) are natural products or are derived from them [16]. 
Despite the difficulties associated with the study and isolation of phytochemicals, they have the 
advantage of greater efficacy than synthetic drugs for some diseases and a lower incidence of side 
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effects. Additionally, a large percentage of the world’s population has no access to conventional 
pharmacological treatments. The different reasons mentioned above describe a situation in which 
research has ample space to improve and simplify extraction protocols and increase the levels of 
metabolites in plants of interest, through classical techniques of genetic improvement or innovative 
biotechnological approaches aimed at modifying biosynthetic pathways, in addition to testing 
substances already isolated for the widest possible spectrum of biological activities. 
1.1. Terpenes and Terpenoids 
Among the many biologically active substances of plant origin, a great deal of attention has been 
paid to terpenes, which are composed of isoprene subunits. More than 30,000 terpenes have been 
isolated thus far [17]. Terpenes are classified as mono-, sesqui-, di-, ses-, tri-, and tetraterpenes 
according to the number of isoprenoid units. The carbon skeleton may be acyclic, or they may possess 
mono-, bi-, tri-, tetra-, and pentacyclic structures [18–24]. Terpenes are of widespread and can be 
found in all organisms, both prokaryotic and eukaryotic. However, most bioactive terpenes have been 
detected in higher plants. Whereas mono- and sesquiterpenes are predominantly found in essential 
plant oils, the higher terpenes, including triterpenes, are found in balsams and resins [25,26]. 
Triterpenoids in their free form (sapogenins), bound to glycosides (saponins) or acetylated are 
particularly important and are ubiquitous throughout the plant kingdom; both in vitro and in vivo 
studies have shown that they also have important biological functions. Because of their relatively 
complex structures, terpenoids are usually referred to by trivial names instead of using systematic 
IUPAC nomenclature. 
1.2. Classification of Terpenoids and Their Biological Effects 
Based on the number of sugars present, saponins are classified as monodesmosides, with a single 
saccharide chain generally linked to C-3; bidesmosides, with two sugar chains linked to C-3 and C-28; 
and tridesmosides, with three saccharide chains. The sugars can be linear or branched; the most 
widespread saccharides in triterpenoid saponins are D-glucose, D-galactose, L-arabinose, L-rhamnose, 
D-xylose, D-fucose and glucuronic acid [27]. The biological effects of such terpenoids are very 
different, and can be summarised as follows: antitumor, antiviral, antidiabetic, anti-inflammatory, 
hepatoprotective, analgesic, antimicrobial, antimycotic, virostatic, immunomodulatory, and tonic 
activities [17]. A few compounds, such as corosolic acid, a dietary supplement against diabetes, are 
already on the market, and several others are in clinical trials or are to be launched soon.  
Many triterpenes exhibit significant biological activity, but several triterpenoids possess haemolytic 
and cytostatic properties that restrict their pharmaceutical use. To overcome these limitations  
and to expand the range of usable triterpenes, transformation of the compound by chemical or 
biotechnological techniques is possible. They are also of extreme interest to the agrochemical field 
because they are involved in the defence mechanisms of plants. Their biological activities are mainly 
related to interactions with cell membranes. The main mechanism of action of saponins against fungi 
appears to be related to their ability to form complexes with sterols in fungal membranes by altering 
the membrane integrity [28]. 
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2. Triterpenoids from Gymnema sylvestre and Their Pharmacological Activities 
The triterpenoidic saponins also act against insect pests by forming an insoluble complex with 
cholesterol, which is the precursor in the biosynthesis of the hormone ecdysone. Because cholesterol is 
the only source of sterols for the majority of the insects and a main energy supply, the cholesterol 
linked to saponins cannot be used, which leads to insect death [29]. 
A relevant specific example of a plant that is very interesting for its numerous pharmacological 
properties, which include antidiabetic, anticarcinogenic, and neuroprotective effects is Gymnema sylvestre, 
used as a medicinal plant in Asia for thousands of years. Its properties are attributed to triterpenoidic 
saponins. In light of the considerable interest generated in the chemistry and pharmacological 
properties of G. sylvestre triterpenes and their analogues, we have undertaken this review in an effort 
to summarise the available literature on these promising bioactive natural products. 
The review will detail studies on the isolation, chemistry and bioactivity of the triterpenoids, which 
are presented in the following tables: triterpenoids oxidised at C-23 (Table 1 and Figure 1); their 
isolation, distribution in different parts of the plant, and their NMR spectral data (Table 2); their names 
and physico-chemical characterisation (Tables 3 and 4, respectively); and, finally, the biological 
properties associated with these compounds, with a focus on their potential chemotherapeutic 
applications (Table 5). 
Biological Effects of Triterpenoids 
Diabetes mellitus (DM) is a disease caused by a deficiency or diminished effectiveness of 
endogenous insulin. It is characterised by hyperglycaemia, deranged metabolism and sequelae 
predominantly affecting the vasculature. There are two main types of diabetes mellitus: Type 1, in 
which the body does not produce sufficient insulin; Type 2, due to the resistance to the insulin, often 
initially with normal or increased levels of circulating insulin. In the UK, there were 2.9 million people 
with diabetes in 2011. It is estimated that 5 million people will have diabetes in the UK by 2025. It is 
also estimated that there are approximately 850,000 people who have undiagnosed diabetes. The 
average prevalence of diabetes in the UK is 4.45% of the population, but there are variations between 
countries and regions. The proportion of people with diabetes increases with age. However, the 
incidence of diabetes is increasing in all age groups. Type 1 diabetes is increasing in children 
(especially those < 5 years of age), and type 2 diabetes is increasing, particularly in black and minority 
ethnic groups. In general, the prevalence of diabetes mellitus and its percentages in different 
populations is almost the same throughout the world. 
Compounds 1−12, 15−20, 39−43 were tested for their antisweet activity. The antisweet activity was 
tested on a group of volunteers who held a solution of the tested compounds (5 mL of the specific 
compounds solution in 0.01 M NaHCO3) in their mouth for 3 min, spat, and rinsed with distilled water. 
The subjects were directed to taste 10 sucrose solutions from 0.1 to 1.0 M. The activity of the 
compound tested was expressed at the maximum concentration of a sucrose solution whose sweetness 
was suppressed completely. 0.5 mM of a solution of gymnemic acids I (1) and II (2) led a complete 
suppression of sweetness induced by 0.4 mM sucrose. More precisely, application of a 1 mM solution 
of 1 and 2 orally led to a complete suppression of sweetness induced by 0.2 and 0.4 M sucrose, 
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respectively [30]. A 1.0 mM solution of gymnemic acids III (3), IV (4), V (5) and VI (6) led to a 
complete suppression of sweetness induced by 0.4 mM sucrose [31,32]. The difference between the 
structures of gymnemic acid III and gymnemic acid IV is only the absence or presence of a double 
bond in the acyl group. Kurihara et al. [33] have suggested that the acyl groups might play an 
important role in the generation of the antisweet activity. However, it seems that acyl groups only 
increase the antisweet activity, but are not essential [34]. A 0.5 mM solution of gymnemic acids  
VIII (8), IX (9) and X (10) leads to a complete suppression of the sweet taste of 0.2 M sucrose. The 
results are similar to those for gymnemic acids III and IV, which are acylated at C21 [35]. 
In general, it has been found that the antisweet activity of these saponins decreases with the 
decreasing number of acyl groups. In fact, a 0.5 mM solution of each of the gymnemic acids XI (11) 
and XII (12), as with gymnemic acids I and II, are able to suppress the perception of sweetness due to 
0.4 M sucrose. The results suggest the antisweet activity of a triterpenes is directly proportional to the 
number of acyl groups present in the molecule [35]. A 0.5 M solution of gymnemic acids XV (15), 
XVI (16), XVII (17), and XVIII (18) completely suppressed the sweet taste of 0.4 M sucrose, showing 
the same activity of gymnemic acids I and II [36]. Gymnemic acid VII (7), prosapogenin (20) and 
gymnemagenin (19) were not active at all [30–32]. In particular, gymnemic acid IV is a multidirectional 
antihyperglycaemic agent with antisweet activity [31], glucose uptake inhibitory activity, and gut 
glycosidase inhibitory action [37]. Moreover, the blood glucose lowering effect of gymnemic acid IV 
was higher than glibenclamide, which was used as a control in streptozotocin-diabetic mice [29]. Most 
of these pharmacological effects may synergistically contribute to alleviating type 2 diabetes-related 
symptoms. Thus, gymnemic acid IV may be used as a prophylactic against diabetes through its 
different mechanisms of action [38]. 
A 1.0 mM solution of compounds 41–43 completely reduced the perceived sweetness of 0.1 M 
sucrose; these results correspond to half of the activity of gymnemic acids I−VI. Compounds 39 and 
40 were not active [34]. 
The literature suggests that the pharmacological effects of G. sylvestre extract or its mixture of 
triterpenoids occur through mechanisms such as modulation of incretin activity, stimulation of insulin 
secretion and release, regeneration of β-endocrinocyte Langerhans islets, activation of enzymes 
responsible for glucose utilisation, reduction of glucose and fatty acid assimilation in the small 
intestine, and interference with the sensation of sweetness. It is known that hormones that regulate the 
formation and secretion of hormones by pancreas islets are activated in response to the entry of food 
into the intestine. Release of specific and well-known gastrointestinal hormones (GIP) into the portal 
vein in response to the intraduodenal administration of D-glucose in the presence of G. sylvestre extract 
enriched in gymnemic acids/triterpenoids by inhibitors of certain proposed glucose sensors and 
transporters in the intestinal lumen has been studied experimentally [39]. Intraduodenal administration 
of D-glucose caused a dose-dependent increase in the concentration of portal immunoreactive GIP. 
This suggests that the extract of G. sylvestre leaves or its constituents increases GIP secretion by 
endocrine k-cells in the small intestine [40]. The literature suggests that the hypoglycaemic activity of 
G. sylvestre is due to stimulating the release of insulin (and possibly the regeneration of Langerhans 
islet β-cells) and enzymes responsible for glucose utilisation and inhibition of glucose absorption in the 
bowel [27,41–43]. This means that the hypertrophy of β-endocrinocytes most likely occurs due to the 
effect of G. sylvestre on the increased secretion of GIP [44]. An autogenic hormone in the blood that 
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was correlated with the hypoglycaemic effect was observed in experimental animals with an 
experimental form of immunodependent DM during a study of G. sylvestre activity. 
In Russia, tests of mixtures consisting of G. sylvestre extracts of various purities (certified 
preparations of G. sylvestre dry extracts) in various concentrations in combination with extracts that 
intensify the antioxidant effect (grape stem) and possess immunomodulating and regenerative 
properties are underway. More than 30 different combinations have been investigated in detail in vitro 
and in vivo. Considering these facts, it is obvious that G. sylvestre is a source of biologically  
active substances. 
The very broad spectrum of pharmacological activity for G. sylvestre indicates that the use of its 
extract or its components at various doses and in various combinations improves the condition of latent 
forms of DM (prediabetes), treats insulin-independent DM, prolongs the action of hypoglycaemic 
preparations, and regenerates β-cells for insulin-dependent and insulin-independent DM [45]. Despite 
the results of these studies, only a few metabolites of G. sylvestre have been tested for their effects on 
glucose uptake. Among them, gymnemosaponin V (43) and gymnemic acids I-IV increase the amount 
of insulin in blood plasma in mice with streptozotocin-induced DM after their administration [35,38]. 
The presence of these compounds, but perhaps not only them, could explain that, when G. sylvestre 
extract was used for 21 days after streptozotocin intoxication, it reliably reduced the levels of glucose 
and HbAlc in blood plasma, increased the insulin content, and normalised the concentration of  
high-density lipoproteins (HDL) [28]. The inhibitory activity of some triterpene glycosides was 
examined to determine their impact on the increase in serum glucose level in oral glucose-loaded rats. 
Gymnemoside-b (33) and gymnemic acids III, V, and VII were found to exhibit slight inhibitory 
activity towards the increase of glucose absorption after a single administration of 100 mg/kg, but 
gymnemic acid I and gymnemasaponin, lacked this activity at the same dose. Although the above 
compounds are included in one of three categories (acylated polyhydroxyoleanane 3-O-glucuronide) of 
glucose absorption inhibitors, their activity is much less than that of their analogues [46]. Gymnemic 
acids II and III showed potent inhibitory activities on glucose uptake, which were almost equivalent to 
those of oleanolic acid-3-O-glucuronide and Escin Ia. Gymnemoside-f (37), gymnemic acid IV and 
gymnemasapoin V were also found to inhibit glucose uptake, while gymenomosides-c (34), -d (35), 
and -e (36) lacked this activity. Gymnemic acids II and III showed no effect on the serum glucose 
levels in oral glucose-loaded rats. They exhibited potent inhibitory activity towards glucose uptake in 
rat small intestine fragments [37]. Gymnemic acid V is normally considered to inhibit glucose 
absorption in the small intestine at a concentration of 100 mg/kg. The inhibitory effect is particularly 
marked after 2 h of administration, with values that are quite comparable in absolute terms to those of 
elatosides, escins, and senegasaponins, which were used as controls. Gymnemic acid I shows an effect 
almost 50% higher than that of the control after 2 h despite appearing to be less active after 30 min and 
1 h. A very similar effect that is only slightly smaller than the control or gymnemic acid V was 
demonstrated for gymnemic acid VII and gymnemosides-a (32) and -b (33). In order of decreasing 
activity up to a value of approximately 30% of the control were gymnemic acid II, IV, gymnemasaponins 
IV and V, gymnesaponin II (40) and gymnemic acid III. However, no apparent structure-activity 
relationship was observed [47]. 
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In recent years interest in cancer prevention has grown steadily and urgently, therefore it would be 
particularly important to identify molecules that are able to prevent or avoid the processes of 
carcinogenesis due to substances of which substantially we can’t do without or can’t avoid in our daily 
life. Several anti-inflammatory substances are well known to inhibit the action of tumour promoters in 
the mouse skin carcinogenesis. The compound 46 was found to inhibit the inflammatory reaction 
induced by tumour promoters. This anti-inflammatory activity may play an important role in the 
mechanism of antitumor promotion as it has already been demonstrated [48,49]. The effects of 
compound 46 on the growth of HepG2 cells were measured. Its inhibitory effect was remarkably 
effective (ID50 was 25 µM) as it induced apoptosis at high dose, and with a dose-dependent  
manner [50,51]. Moreover, the application of antitumor-promoting triterpenoids is highly promising 
for protection against tumour formation, and many triterpenoids were tested in vitro and in vivo against 
the action of tumour promoter, 12-O-tetradecanoylphorbol 13-acetate (TPA) induced Epstein-Barr 
virus (EBV) activation in Raji cells. Recently, ursolic and oleanolic acids have been reported to be 
inhibitors of TPA and the dose responses of the acids were very similar to those of the antitumor 
promoters, such as retinoic and glycyrrhetinic acids and their analogues [51,52]. Thus some glycyrrhetinic 
acid-related compounds were found to be inhibitors of tumour promoter-induced phenomenon in vitro. 
Among these compounds, the compound 46 also proved to have in vivo antitumor-promoting activity 
in mouse skin tumour formation induced by 7,12-dimethylbenz[a]anthracene plus tumor promoters 
TPA [50]. Although its mechanism is unknown, the modulation of phospholipid metabolism appeared 
to be a very interesting aspect was proved that the inhibitory potency of the triterpenoids for the  
TPA-enhanced phospholipid synthesis is closely associated with their antitumor-promoting activity. 
Finally, a sulforhodamine B bioassay was used to determine the cytotoxicity of compound 44. Its 
cytotoxic activity against four cultured human tumour cells was examined in vitro. The tumour cell 
lines were A549 (non small cell lung adenocarcinoma), SK-OV-3 (ovarian cancer cells), SK-MEL-2 
(skin melanoma), and HCT15 (colon cancer cells) [53,54]. Doxorubicin was used as the positive control. 
The tested compound was essentially no cytotoxic [55]. A crude extract o mixture of compounds used 
in traditional medicine frequently contains components that have mutually opposing pharmacological 
activities beneficial for a specific disease. The higher potency of a crude drug is probably due to a 
synergistic effect among its component compounds, even though the activity of each compound is 
weak when used alone. This does not mean that it is not relevant to define a complete picture of the 
activities or biological properties of each compound. To identify a particular compound or a mixture of 
those with remarkable properties we should be able to deal with infusions or extracts that may have a 
different composition for an infinite number of reasons (location and/or harvesting season of the plant, 
particularly plant species, manner and time of extraction or partial purification etc.). Furthermore, the 
identification of one or of a few molecules suitable for the purpose would allow us to synthesize them, 
with a process as much as economically or timely convenient and to obtain pure products or  
well-defined composition. 
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Table 1. Common name and relative substituents of triterpenes with olean-12-ene skeleton. 
No. Common Name R1 R2 R3 R4 R5 R6 
1 Gymnemic acid I/3-O-β-D-Glucuronopyranosyl-21-O-tigloyl-28-O-acetyl gymnemagenin GlcA H OH OAc OH OTig
2 Gymnemic acid II/3-O-β-D-Glucuronopyranosyl-21-[S(+)-2-methyl-butyloyl]-28-O-acetyl gymnemagenin GlcA H OH OAc OH OMba
3 Gymnemic acid III/3-O-β-D-Glucuronopyranosyl-21-[S(+)-2-methyl-butyloyl]-gymnemagenin GlcA H OH OH OH OMba
4 Gymnemic acid IV/3-O-β-D-Glucuronopyranosyl-21-O-tigloyl-gymnemagenin GlcA H OH OH OH OTig
5 Gymnemic acid V/3-O-β-D-Glucuronopyranosyl-21,22-bis-tigloyl gymnemagenin GlcA H OH OH OTig OTig
6 Gymnemic acid VI/3-O-[β-D-Glucuronopyranosyl(1→3)-β-D-glucuronopyranosyl]-21-O-tigloyl gymnemagenin A H OH OH OH OTig
7 Gymnemic acid VII/3-O-β-D-Glucuronopyranosylgymnestrogenin GlcA H OH OH H OH 
8 Gymnemic acid VIII B H OH OH OH OMba
9 Gymnemic acid IX B H OH OH OH OTig
10 Gymnemic acid X/3-O-β-D-Glucuronopyranosyl-28-O-acethyl gymnemagenin GlcA H OH OAc OH OH 
11 Gymnemic acid XI/3-O-β-D-Glucuronopyranosyl-21,28-bis-O-tigloyl gymnemagenin GlcA H OH OTig OH OTig
12 
Gymnemic acid XII/3-O-β-D-Glucuronopyranosyl (1→3)-
O-β-D-glucopyranosyl-21-O-tigloyl-28-O-acetyl 
gymnemagenin 
A H OH OAc OH OTig
13 Gymnemic acid XIII GlcA H OH OMba OH OH 
14 Gymnemic acid XIV GlcA H OH OTig OH OH 
15 Gymnemic acid XV/3-O-β-D-Glucuronopiranosyl-21-O-2-methylbutyryl-22-O-2-methylcrotonoylgymnemagenin GlcA H OH OH OTig OMba
16 Gymnemic acid XVI/3-O-β-D-Glucuronopiranosyl 16,22-O-bis-2-methylcrotonoylgymnemagenin GlcA H Tig OH OTig OH 
17 Gymnemic acid XVII/3-O-β-D-Glucuronopiranosyl-21-O-benzoyl gymnemagenin GlcA H OH OH OH OBz 
18 Gymnemic acid XVIII/3-O-β-D-Glucuronopiranosyl-28-O-benzoyl gymnemagenin GlcA H OH OBz OH OH 
19 Gymnemagenin/3β,16β,21β,22α,23,28-hexahydroxyolean-12-ene H H OH OH OH OH 
20 Prosapogenin/3-O-β-D-Glucuronopyranosyl gymnemagenin GlcA H OH OH OH OH 
21 12-Oleanene-3β,16β,23,28-tetrol/23-Hydroxylongispinogenin H H OH OH H H 
22 3,16,23,28-O-Tetraacetyl 3β,16β,23,28-tetrahydroxyolean-12-ene OAc OAc OAc OAc H H 
23 21-O-(2S)-Methylbutanoyl 3β,16β,21β,22α,23,28-hexahydroxyolean-12-ene H H OH OH OH OMba
24 28-O-acetyl 21-O-(2S)-methylbutanoyl 3β,16β,21β,22α,23,28-hexahydroxyolean-12-ene H H OH OAc OH OMba
25 3,16,22,23,28-O-Pentaacetyl 21-O-(2S)-methylbutanoyl 3β,16β,21β,22α,23,28-hexahydroxyolean-12-ene OAc OAc OAc OAc OAc OMba
26 21-O-Tigloyl 3β,16β,21β,22α,23,28-hexahydroxyolean-12-ene H H OH OH OH OTig
27 Gymnemanol/3β,16β,22α,23,28-pentahydroxyolean-12-en H H OH OH OH H 
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Table 1. Cont. 
No. Common Name R1 R2 R3 R4 R5 R6 
28 Gymnemasin A/3-O-[β-D-Gluconopyranosyl(1→3)-β-
D-glucuronopyranosyl]-22-O-tigloyl gymnemanol A H OH OH OTig H 
29 Gymnemasin B/3-O-[β-D-Gluconopyranosyl(1→3)-β-
D-glucuronopyranosyl]-gymnemanol A H OH OH OH H 
30 Gymnemasin C/3-O-β-D-glucuronopyranosyl-22-tigloyl gymnemanol GlcA H OH OH OTig H 
31 Gymnemasin D/3-O-β-D-glucuronopyranosylgymnemanol GlcA H OH OH OH H 
32 
Gymnemoside-a/21-O-Tigloyl-22-O-
acetylgymnemagenin 3-O-β-D-glucupyranosiduronic 
acid 
GlcA H OH OH OAc OTig
33 Gymnemoside-b/16-O-Acetyl-21-O-tigloyl-gymnemagenin 3-O-β-D-glucupyranosiduronic acid GlcA H OAc OH OH OTig
34 
Gymnemoside-c/21-O-Benzoyl-28-O-
acetylgymnemagenin 3-O-β-D-glucupyranosiduronic 
acid 
GlcA H OH OAc OH OBz
35 
Gymnemoside-d/23-O-[β-D-Xylopyranosyl (1→6)-β-
D-glucopyranosyl (1→6)-β-D-glucopyranosyl] 
gymnestrogenin 
H D OH OH H OH 
36 
Gymnemoside-e/23-O-[β-D-Xylopyranosyl(1→6)-β-
D-glucopyranosyl (1→6)-β-D-glucopyranosyl]-28-O-
[β-D-glucopyranosyl(1→6)-β-D-glucopyranosy] 23-
hydroxylongispinogenin 
H D OH C H H 
37 
Gymnemoside-f/23-O-[β-D-Xylopyranosyl(1→6)-β-
D-glucopyranosyl (1→6)-β-D-glucopyranosyl]-28-O-
[9-D-glucopyranosyl (1→6)-β-D-glucopyarnosyl] 
3β,16β,23,28-tetrahydroxyolean-18-ene 
See Figure 2 
38 
23-O-[β-D-Glucopyranosyl (1→6)-β-D-
glucopyranosyl]-oleanene-3β,16β,23,28-tetrol/(+)-28-
O-Desglucosylgymnemasaponin IV 
H C OH OH H H 
39 Gymnemasaponin I H H OH Glc H H 
40 Gymnemasaponin II H Glc OH Glc H H 
41 Gymnemasaponin III H Glc OH C H H 
42 Gymnemasaponin IV H C OH Glc H H 
43 Gymnemasaponin V H C OH C H H 
44 Gymnestrogenin/3β,16β,21β,23,28-Pentahydroxyolean-12-ene H H OH OH H OH 
45 3β,16α,23,28-Tetrahydroxyolean-12-ene See Figure 2 
46 3β,23,28-Trihydroxyolean-12-ene  H H H OH H H 
47 3β,16β,21β,23-Tetrahydroxyolean-12-ene  See Figure 2 
48 3β,16β,21β,23,28-Pentahydroxyolean-12-ene  H H OH OH H OH 
49 3β,16β,21α,23,28-Pentahydroxyolean-12-ene  See Figure 2 
50 3β,16β,23,28-Tetrahydroxyolean-13(18)-ene See Figure 2 
51 16β,23,28-Trihydroxyolean-12-en-3-one  See Figure 2 
52 16β,21β,23,28-Tetrahydroxyolean-12-en-3-one  See Figure 2 
53 16β,21β,22α,23,28-Pentahydroxyolean-12-en-3-one  
For partial structures Glc, GlcA, A, B, C, and D see Figure 1. 
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Figure 1. Chemical structures of triterpenes isolated from G. sylvestre. 
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Figure 2. Chemical structures of compounds 37, 45, 47, 49–53. 
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Table 2. Isolation and distribution of triterpenes in the different parts of the plants and their 
NMR spectral data. 
No. 
Part of 
the Plant 
Extract Ref. Aspect 
Solvents of NMR Spectra 
1H-NMR 13C-NMR Ref. 
1 Leaves 
H2O 
CH3OH 
[31] 
[46] / C5D5N C5D5N [31,35] 
2 Leaves 
H2O 
CH3OH 
[31] 
[46] / C5D5N C5D5N [31] 
3 Leaves 
H2O 
CH3OH 
[31] 
[46] Colourless powder C5D5N C5D5N [30,31,56]
4 Leaves 
H2O 
CH3OH 
[31] 
[46] 
Colourless powder C5D5N C5D5N [30,31,56]
5 Leaves 
H2O 
CH3OH 
[32,46] Colourless powder C5D5N C5D5N [32,56] 
6 Leaves H2O [32] / C5D5N C5D5N [32] 
7 
Leaves 
Leaves 
H2O 
CH3OH 
[32,46] / C5D5N C5D5N [32] 
8 Leaves H2O [56] Colourless powder C5D5N+D2O C5D5N+D2O [56] 
9 Leaves H2O [56] Colourless powder C5D5N+D2O C5D5N+D2O [56] 
10 Leaves H2O:EtOH (2:3) [35] 
Amorphous white 
powder C5D5N C5D5N [35] 
11 Leaves H2O:EtOH (2:3) [35] 
Amorphous white 
powder C5D5N C5D5N [35] 
12 Leaves H2O:EtOH (2:3) [35] 
Amorphous white 
powder C5D5N C5D5N [35] 
13 Leaves H2O:EtOH (2:3) [35] Amorphous powder C5D5N C5D5N [35] 
14 Leaves H2O:EtOH (2:3) [35] Amorphous powder C5D5N C5D5N [35] 
15 Leaves H2O:EtOH (2:3) [36] 
Amorphous white 
powder C5D5N C5D5N [36] 
16 Leaves H2O:EtOH (2:3) [36] 
Amorphous white 
powder C5D5N C5D5N [36] 
17 Leaves H2O:EtOH (2:3) [36] 
Amorphous white 
powder C5D5N C5D5N [36] 
18 Leaves H2O:EtOH (2:3) [36] 
Amorphous white 
powder C5D5N C5D5N [36] 
19 Leaves Microwave [51] 
[32] / C5D5N 
C5D5N 
CDCl3+CD3OD 
[31,56] 
[57] By synthesis 
20 By synthesis [32] / C5D5N 
C5D5N 
CD3OD 
[31,56] 
[57] 
21 Aerial parts CH2Cl2 [58] Amorphous powder CD3OD CD3OD [58] 
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Table 2. Cont. 
No. 
Part of 
the Plant 
Extract Ref. Aspect 
Solvents of NMR Spectra 
1H-NMR 13C-NMR Ref. 
22 Aerial parts CH2Cl2 [58] Amorphous powder CD3OD CD3OD [58] 
23 Aerial parts CH2Cl2 [58] Amorphous powder CD3OD CD3OD [58] 
24 Aerial parts CH2Cl2 [58] Amorphous powder CD3OD CD3OD [58] 
25 Aerial parts CH2Cl2 [58] Amorphous powder CD3OD CD3OD [58] 
26 Aerial parts CH2Cl2 [58] Amorphous powder CD3OD CD3OD [58] 
27 By synthesis [59] Micro-needles C5D5N C5D5N [59] 
28 Leaves H2O:EtOH (1:1) [59] Amorphous powder C5D5N C5D5N [59] 
29 Leaves H2O:EtOH (1:1) [59] Amorphous powder C5D5N C5D5N [59] 
30 Leaves H2O:EtOH (1:1) [59] Amorphous powder C5D5N C5D5N [59] 
31 Leaves H2O:EtOH (1:1) [59] Amorphous powder C5D5N C5D5N [59] 
32 Leaves CH3OH [46] Colourless fine crystals C5D5N C5D5N [46] 
33 Leaves CH3OH [46] Colourless fine crystals C5D5N C5D5N [46] 
34 Leaves CH3OH [46] Colourless fine crystals C5D5N C5D5N [37] 
35 Leaves CH3OH [46] Colourless fine crystals C5D5N C5D5N [37] 
36 Leaves CH3OH [46] Colourless fine crystals C5D5N C5D5N [37] 
37 Leaves CH3OH [46] Colourless fine crystals C5D5N C5D5N [37] 
38 By synthesis [34] / C5D5N C5D5N [34] 
39 Leaves H2O:EtOH (1:1) [34] / C5D5N C5D5N [34] 
40 Leaves 
CH3OH 
H2O:EtOH (1:1) 
[46] 
[34] 
/ C5D5N C5D5N [34] 
41 Leaves H2O:EtOH (1:1) [34] / C5D5N C5D5N [34] 
42 Leaves 
CH3OH 
H2O:EtOH (1:1) 
[46] 
[34] 
/ C5D5N C5D5N [34] 
43 Leaves 
CH3OH 
H2O:EtOH (1:1) 
[46] 
[34] 
/ C5D5N C5D5N [34] 
44 
Aerial parts H2O [32,60] / C5D5N C5D5N [32] By synthesis 
45 Aerial parts H2O [57] Amorphous powder 
CD3OD 
CDCl3 
CD3OD 
CDCl3 
[58] 
[61] 
46 Aerial parts CH2Cl2 [60] / CDCl3 CDCl3 [62] 
47 Aerial parts CH2Cl2 [60] Amorphous powder CD3OD CD3OD [60] 
48 Aerial parts CH2Cl2 [60] / C5D5N C5D5N [32] 
49 Aerial parts CH2Cl2 [60] Amorphous powder CD3OD CD3OD [60] 
50 Aerial parts CH2Cl2 [60] Amorphous powder CD3OD CD3OD [60] 
51 Aerial parts CH2Cl2 [60] Amorphous powder CD3OD CD3OD [60] 
52 Aerial parts CH2Cl2 [60] Amorphous powder CD3OD CD3OD [60] 
53 Aerial parts CH2Cl2 [60] Amorphous powder CD3OD CD3OD [60] 
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Table 3. Systematic names and physico-chemical characterization of triterpenes-1. 
No. Systematic Name CAS 
Molecular
Formula 
Molecular 
Weight 
Melting 
Point °C
Ref. 
1 
β-D-Glucopyranosiduronic acid, 
(3β,4α,16β,21β,22α)-28-(acetyloxy)-16,22,23-
trihydroxy-21-[[(2E)-2-methyl-1-oxo-2-buten-
1-yl]oxy]olean-12-en-3-yl 
122,168-
40-5 
C43H66O14 806.97 211–212 [31] 
2 
β-D-Glucopyranosiduronic acid, 
(3β,4α,16β,21β,22α)-28-(acetyloxy)-16,22,23-
trihydroxy-21-[(2S)-2-methyl-1-
oxobutoxy]olean-12-en-3-yl 
122,144-
48-3 
C43H68O14 808.99 212–213 [31] 
3 
β-D-Glucopyranosiduronic acid, 
(3β,4α,16β,21β,22α)-16,22,23,28-tetrahydroxy-
21-[(2S)-2-methyl-1-oxobutoxy]olean-12-en-3-
yl 
122,074-
65-1 
C41H66O13 766.95 
219–221 
218–219
[56] 
[31] 
4 
β-D-Glucopyranosiduronic acid, 
(3β,4α,16β,21β,22α)-16,22,23,28-tetrahydroxy-
21-[[(2E)-2-methyl-1-oxo-2-buten-1-
yl]oxy]olean-12-en-3-yl 
121,903-
96-6 
C41H64O13 764.94 
229–231 
210–221
[56] 
[31] 
5 
β-D-Glucopyranosiduronic acid, 
(3β,4α,16β,21β,22α)-16,23,28-trihydroxy-
21,22-bis[[(2E)-2-methyl-1-oxo-2-butenyl]-
oxy]olean-12-en-3-yl 
121,903-
99-9 
C46H70O14 847.04 
214–216 
202–203
[56] 
[32] 
6 
β-D-Glucopyranosiduronic acid, 
(3β,4α,16β,21β,22α)-16,22,23,28-tetrahydroxy-
21-[[(2E)-2-methyl-1-oxo-2-butenyl]oxy]olean-
12-en-3-yl 3-O-β-D-glucopyranosyl 
121,903-
98-8 
C47H74O18 927.08 225–226 [32] 
7 
β-D-Glucopyranosiduronic acid, 
(3β,4α,16β,21β)-16,21,23,28-
tetrahydroxyolean-12-en-3-yl 
121,903-
97-7 
C36H58O11 666.84 222–223 [32] 
8 
β-D-Glucopyranosiduronic acid, 
[3β,4α,16β,21β(S),22α]-16,22,23,28-
tetrahydroxy-21-(2-methyl-1-oxobutoxy)olean-
12-en-3-yl 3-O-β-D-arabino-hexopyranos-2-
ulos-1-yl 
131,653-
19-5 
C47H74O18 927.08 218–220 [56] 
9 
β-D-Glucopyranosiduronic acid, 
[3β,4α,16β,21β(E),22α]-16,22,23,28-
tetrahydroxy-21-[(2-methyl-1-oxo-2-
butenyl)oxy]-olean-12-en-3-yl 3-O-β-D-
arabino-hexopyranos-2-ulos-1-yl 
131,653-
20-8 
C47H72O18 925.06 222–224 [56] 
10 
β-D-Glucopyranosiduronic acid, 
(3β,4α,16β,21β,22α)-28-(acetyloxy)-
16,21,22,23-tetrahydroxyolean-12-en-3-yl 
147,934-
05-2 
C38H60O13 724.86 210–212 [35] 
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Table 3. Cont. 
No. Systematic Name CAS 
Molecular
Formula 
Molecular 
Weight 
Melting
Point °C
Ref. 
11 
β-D-Glucopyranosiduronic acid, 
(3β,4α,16β,21β,22α)-16,22,23-trihydroxy-
21,28-bis[[(2E)-2-methyl-1-oxo-2-
butenyl]oxy]-olean-12-en-3-yl 
147,899-35-2 C46H70O14 847.04 190–192 [35] 
12 
β-D-Glucopyranosiduronic acid, 
(3β,4α,16β,21β,22α)-28-(acetyloxy)-
16,22,23-trihydroxy-21-[[(2E)-2-methyl-1-
oxo-2-butenyl]oxy]olean-12-en-3-yl 3-O-β-
D-glucopyranosyl 
147,899-36-3 C49H76O19 968.50 209–211 [35] 
13 
β-D-Glucopyranosiduronic acid, 
(3β,4α,16β,21β,22α)-16,21,22,23-
tetrahydroxy-28-[(2S)-2-methyl-1-
oxobutoxy]olean-12-en-3-yl 
155,023-61-3 C41H66O13 766.95 185–187 [35] 
14 
β-D-Glucopyranosiduronic acid, 
(3β,4α,16β,21β,22α)-16,21,22,23-
tetrahydroxy-28-[[(2E)-2-methyl-1-oxo-2-
butenyl]oxy]olean-12-en-3-yl 
155,023-62-4 C41H64O13 764.94 194–196 [35] 
15 
β-D-Glucopyranosiduronic acid, 
(3β,4α,16β,21β,22α)-16,23,28-trihydroxy-
22-[[(2E)-2-methyl-1-oxo-2-butenyl]oxy]-
21-(2-methyl-1-oxobutoxy)olean-12-en-3-
yl 
154,977-74-9 C46H72O14 849.06 / / 
16 
β-D-Glucopyranosiduronic acid, 
(3β,4α,16β,21β,22α)-21,23,28-trihydroxy-
16,22-bis[[(2E)-2-methyl-1-oxo-2-
butenyl]oxy]olean-12-en-3-yl 
154,977-75-0 C46H70O14 847.04 203–205 [36] 
17 
Gymnemic acid XVII/β-D-
Glucopyranosiduronic acid, 
(3β,4α,16β,21β,22α)-21-(benzoyloxy)-
16,22,23,28-tetrahydroxyolean-12-en-3-yl 
154,977-76-1 C43H62O13 786.94 211–213 [36] 
18 
β-D-Glucopyranosiduronic acid, 
(3β,4α,16β,21β,22α)-28-(benzoyloxy)-
16,21,22,23-tetrahydroxyolean-12-en-3-yl 
154,977-77-2 C43H62O13 786.94 201–203 [36] 
19 
Olean-12-ene-3,16,21,22,23,28-hexol, 
(3β,4α,16β,21β,22α) 22,467-07-8 C30H50O6 506.71 
313–314
>300 
328–335
[32,35]
[56] 
[63] 
20 
β-D-Glucopyranosiduronic acid, 
(3β,4α,16β,21β,22α)-3,16,21,22,23,28-
hexahydroxyolean-12-en-3-yl 
50,647-08-0 C36H58O11 666.84 230–231 [32,35]
21 3β,16β,23,28-Tetrahydroxyolean-12-ene 42,483-24-9 C30H50O4 474.72 / [58] 
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Table 3. Cont. 
No. Systematic Name CAS Molecular Formula 
Molecular 
Weight 
Melting 
Point °C Ref.
22 3,16,23,28-O-Tetraacetyl 3β,16β,23,28-tetrahydroxyolean-12-ene / C38H59O7 627.87 / [58]
23 
21-O-(2S)-Methylbutanoyl 
3β,16β,21β,22α,23,28-hexahydroxyolean-
12-ene 
/ C35H59O7 591.84 / [58]
24 
28-O-Acetyl 21-O-(2S)-methylbutanoyl 
3β,16β,21β,22α,23,28-hexahydroxyolean-
12-ene 
/ C37H61O7 617.88 / [58]
25 
3,16,22,23,28-O-Pentaacetyl 21-O-(2S)-
methylbutanoyl 3β,16β,21β,22α,23,28-
hexahydroxyolean-12-ene 
/ C45H68O11 785.01 / [58]
26 21-O-Tigloyl 3β,16β,21β,22α,23,28-hexahydroxyolean-12-ene / C35H57O6 573.82 / [58]
27 Olean-12-ene-3,16,22,23,28-pentol, (3β,4α,16β,22α) 
174,324-
52-8 C30H50O5 490.72 284–285 [59]
28 
β-D-Glucopyranosiduronic acid, 
(3β,4α,16β,22α)-16,23,28-trihydroxy-22-
[[(2E)-2-methyl-1-oxo-2-
butenyl]oxy]olean-12-en-3-yl 3-O-β-D-
glucopyranosyl 
174,324-
49-3 C47H74O17 910.49 215–217 [59]
29 
β-D-Glucopyranosiduronic acid, 
(3β,4α,16β,22α)-16,22,23,28-
tetrahydroxyolean-12-en-3-yl 3-O-β-D-
glucopyranosyl 
174,324-
48-2 C42H68O16 828.45 221–222 [59]
30 
β-D-Glucopyranosiduronic acid, 
(3β,4α,16β,22α)-16,23,28-trihydroxy-22-
[[(2E)-2-methyl-1-oxo-2-
butenyl]oxy]olean-12-en-3-yl 
174,324-
50-6 C41H64O12 748.44 212–214 [59]
31 
β-D-Glucopyranosiduronic acid, 
(3β,4α,16β,22α)-16,22,23,28-
tetrahydroxyolean-12-en-3-yl 
174,324-
51-7 C36H58O11 666.40 220–221 [59]
32 
β-D-Glucopyranosiduronic acid, 
(3β,4α,16β,21β,22α)-22-(acetyloxy)-
16,23,28-trihydroxy-21-[[(2E)-2-methyl-1-
oxo-2-buten-1-yl]oxy]olean-12-en-3-yl 
175,033-
15-5 C43H66O14 806.98 207.0–208.5 [46]
33 
β-D-Glucopyranosiduronic acid, 
(3β,4α,16β,21β,22α)-16-(acetyloxy)-
22,23,28-trihydroxy-21-[[(2E)-2-methyl-1-
oxo-2-buten-1-yl]oxy]olean-12-en-3-yl 
174,232-
51-0 C43H66O14 806.98 211.5–213.0 [46]
34 
β-D-Glucopyranosiduronic acid, 
(3β,4α,16β,21β,22α)-28-(acetyloxy)-21-
(benzoyloxy)-16,22,23-trihydroxyolean-12-
en-3-yl 
199,618-
65-0 C45H64O14 828.98 211.5–213.0 [37]
35 
β-D-Glucopyranoside, (3β,4α,16β,21β)-
3,16,21,28-tetrahydroxyolean-12-en-23-yl 
O-β-D-xylopyranosyl-(1→6)-O-β-D-
glucopyranosyl-(1→6)-β-D-glucopyranosyl
199,618-
66-1 C47H78O19 947.11 219.1–221.0 [37]
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Table 3. Cont. 
No. Systematic Name CAS MolecularFormula 
Molecular 
Weight 
Melting 
Point °C Ref. 
36 
β-D-Glucopyranoside, (3β,4α,16β)-3,16-
dihydroxy-23-[(O-β-D-xylopyranosyl-
(1→6)-O-β-D-glucopyranosyl-(1→6)-β-D-
glucopyranosyl)oxy]olean-12-en-28-yl 6-
O-β-D-glucopyranosyl 
199,618-
67-2 C59H98O28 1255.39 
202.8–
204.1 [37] 
37 
β-D-Glucopyranoside, (3β,4α,16β)-3,16-
dihydroxy-23-[(O-β-D-xylopyranosyl-
(1→6)-O-β-D-glucopyranosyl-(1→6)-β-D-
glucopyranosyl)oxy]olean-18-en-28-yl 6-
O-β-D-glucopyranosyl 
199,618-
68-3 
 
C59H98O28 
 1255.39 
201.3–
203.2 [37] 
38 
β-D-Glucopyranoside, (3β,4α,16β)-3,16,28-
trihydroxyolean-12-en-23-yl 6-O-β-D-
glucopyranosyl 
133,629-
85-3 C42H70O14 799.00 173–175 [34] 
39 β-D-Glucopyranoside,(3β,4α,16β)-3,16,23-trihydroxyolean-12-en-28-yl 
133,629-
80-8 C36H60O9 636.86 184–185 [34] 
40 β-D-Glucopyranoside, (3β,4α,16β)-3,16-dihydroxyolean-12-ene-23,28-diyl bis 
133,629-
81-9 C42H70O14 799.00 190–192 [34] 
41 
β-D-Glucopyranoside, (3β,4α,16β)-23-(β-D-
glucopyranosyloxy)-3,16-dihydroxyolean-
12-en-28-yl 6-O-β-D-glucopyranosyl 
133,629-
82-0 C48H80O19 961.14 203–205 [34] 
42 
β-D-Glucopyranoside, (3β,4α,16β)-28-(β-D-
glucopyranosyloxy)-3,16-dihydroxyolean- 
12-en-23-yl 6-O-β-D-glucopyranosyl 
133,629-
83-1 C48H80O19 961.14 201–203 [34] 
43 
β-D-Glucopyranoside, (3β,4α,16β)-3,16-
dihydroxyolean-12-ene-23,28-diyl bis[6-O-
β-D-glucopyranosyl] 
133,629-
84-2 C54H90O24 1123.28 186–188 [34,37]
44 Olean-12-ene-3,16,21,23,28-pentol, (3β,4α,16β,21β) 
19,942-02-
0 C30H50O5 490.72 290–291 [32] 
45 Olean-12-ene-3,16,23,28-tetrol, (3β,4α,16β) 
23,887-98-
1 C30H50O4 474.72  [64] 
46 (3β-Olean-12-ene-3,23,28-triol  35,043-82-4 C30H50O3 458.72 / [62] 
47 (3β,16β,21β-Olean-12-ene-3,16,21,23-tetrol 1,447,214-81-4 C30H50O4 474.72 / [62] 
48 (3β,16β,21β-Olean-12-ene-3,16,21,23,28-pentol  
42,483-24-
9 C30H50O4 474.72 / [62] 
49 (3β,16β,21α-Olean-12-ene-3,16,21,23,28-pentol  
1,447,214-
84-7 C30H50O5 490.72 / [62] 
50 (3β,16β-Olean-13(18)-ene-3,16,23,28-tetrol 26,540-63-6 C30H50O4 474.72 / [62] 
51 16β,23,28-Tetrahydroxyolean-12-en-3-one 1,447,214-87-0 C30H48O4 472.70 / [62] 
52 16β,21β,23,28-Tetrahydroxyolean-12-en-3-one  
1,447,214-
89-2 C30H48O5 488.70 / [62] 
53 16 β,22α,23,28-Tetrahydroxyolean-12-en-3-one  
1,447,214-
91-6 C30H48O5 488.70 / [62] 
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Table 4. Physico-chemical characterization of triterpenes-2. 
No. MS Analysis IR υmax, cm−l [α]D (c, MeOH) Ref. 
1 / / +36.7° (2.4) [31] 
2 / / +36.3° (1.5) [31] 
3 / 3400 (OH), 1715 (C=O) +9.6° (0.39) [56] 
4 / 3400 (OH), 1700 (C=O) +7.4° (0.21) [56] 
5 
/ 
FAB(+): 892 [M + 2Na]+ 
3400 (OH), 1700 (C=O) 
/ 
+3.3° (0.30) 
+2.2° (3.6) 
[56] 
[32] 
6 FAB(+): 972 [M + 2Na]+ / +11.7° (1.1) [32] 
7 FAB(+): 712 [M + 2Na]+ / +9.6° (5.7) [32] 
8 HR-FAB(+): 949.4818 [M + Na]+ 3450 (OH), 1730 (C=O) +17.3° (0.74) [56] 
9 HR-FAB(+): 947.4681 [M + Na]+ 
3400 (OH), 1730 (C=O), 
1700 (C=O) 
+11.4° (0.70) [56] 
10 FAB(−): 723[M − H]− 3400 (OH), 1740 (C=O), 
1610 (C=C), 1040 (OH) 
+14.9° (2.3) [35] 
11 FAB(−): 845 [M − H]− 3400 (OH), 1740 (C=O), 
1610 (C=C), 1040 (OH) 
+1.7° (5.3) [35] 
12 FAB(−): 967 [M − H]− 
3400 (OH), 1740 (C=O), 
1720 (C=O), 1610 (C=C), 
1040 (OH) 
+11.7° (3.6) [35] 
13 FAB(−): 765 [M − H]− 3400 (OH), 1720 (C=O), 
1600 (C=C), 1040 (OH) 
+21.5° (3.5) [35,36]
14 FAB(−): 763 [M − H]− 3380 (OH), 1705 (C=O), 
1605 (C=C), 1060 (OH). 
+7.6° (1.8) [35,36]
15 
FAB(−): 847 [M − H]−, 747 [M − H − 
C5H8O2]−, 
745 [M − H − C5H10O2]−, 645 [M − H − 
C5H8O2-C5H10O2]− 
3400 (OH), 1740 (C=O), 
1720 (C=O), 1610 (C=C), 
1040 (OH) 
+7.2° (1.52) [36] 
16 
FAB(−): 845 [M − H]−, 745 [M − H − 
C5H8O2]−, 
645 [M – H − 2C5H8O2]− 
3380 (OH), 1740 (C=O), 
1650 (C=C), 1050 (OH) 
−6.8° (2.96) [36] 
17 
FAB(−): 785 [M − H]−, 663 [M − H − 
C7H6O2]− 
3450 (OH), 1700 (C=O), 
1720 (C=O), 1605(C=C), 
1060 (OH) 
+7.1° (2.96) [36] 
18 
FAB(−): 785 [M − H]−, 663 [M − H − 
C7H6O2]− 
3400 (OH), 1700 (C=O), 
1650 (C=C), 1040 (OH) 
+6.4° (1.71) [36] 
19 
FAB(+): 529 [M + Na]+ 
FAB(+): 506 [M]+, 488 [M − H2O]+ 
HR-ESI-MS: 507.3678 [M + H]+ 
/ 
/ 
3328, 1111, 1089, 1037 
+53.5° (1.8) 
+53.9° (0.75) 
−1.2° (0.19) 
[32,35]
[56] 
[58] 
20 
FAB(+): 705 [M + Na]+ 
728 [M + 2Na]+ 
/ 
/ 
+8.4° (1.8) 
+8.4° (1.8) 
[35] 
[32] 
21 
ESI-MS: 475.2 [M + H]+. HR-ESI-MS: 
475.3780 [M + H]+ 
FAB(+): 497 [M + Na]+ 
3345, 1132, 1077, 1038 
 
−0.67° (0.22) 
+32.0° (2.8) 
[58] 
[34,61]
22 HR-ESI-MS: 643.4204 [M + H]+ 
3333, 1758, 1754, 1117, 1091, 
1033 
+50.0° (0.23) [58] 
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23 HR-ESI-MS: 591.4254 [M + H]+ 3370, 1747, 1118, 1096, 1046 +3.5° (0.21) [58] 
24 HR-ESI-MS: 633.4360 [M + H]+ 3352, 1746, 1113, 1091, 1041 +16.5° (0.2 ) [58] 
25 HR-ESI-MS: 801.4782 [M + H]+ 
3355, 1764, 1750, 1113, 1090, 
1042 
+2.5° (0.21) [58] 
26 HR-ESI-MS: 589.4099 [M + H]+ 3352, 17,252, 1113, 1093, 1041 +3.5° (0.22) [58] 
27 
EI: 490 [M]+, 472 [M − H2O]+,  
454 [M − 2H2O]+  
441 [M − H2O − CH2OH]+, 436 [M − 
3H2O]+ 
3350 (OH) +51.5° (1.0) [59] 
28 
FAB(+): 933 [M + Na]+. FAB(−):  
909 [M − H]− 
3400 (OH), 1715 (C=O), 1600 
(C=C) 
+15° (1.5) [59] 
29 FAB(−): 827 [M − H]− 3420 (OH), 1710 (C=O) +18.5° (1.0) [59] 
30 FAB(−): 747 [M − H]− 3410 (OH), 1715 (C=O) +12.5° (1.0) [59] 
31 FAB(−): 665 [M − H]− 3425 (OH),1715 (C=O) +8° (0.9) [59] 
32 
HR-FAB(−): 805.4385 [M − H]−  
HR-FAB(+): 829.4430 [M − Na]+ 3453, 1721, 1649, 1040 +4.7° (0.1) [46] 
33 
HR-FAB(−): 805.4404 [M − H]−  
HR-FAB(+): 829.4428 [M − Na]+ 3445, 1718, 1649, 1044 +6.6° (0.1) [46] 
34 
HR-FAB(+): 829.4360 [M + Na]+ 
FAB(+): 851 [M + Na]+. FAB(−):  
827 [M − H]− 
3445, 1718, 1649, 1044 +6.6° (0.1) [37] 
35 
HR-FAB(+): 969.5050 [M + Na]+ 
FAB(+): 991 [M + 2Na − H]+, 969 [M + 
Na]+. FAB(−): 945 [M − H]− 
3410, 1044 +13.4° (0.1) [37] 
36 
HR-FAB(−): 1253.6154 [M − H]−, 
FAB(+): 1277 [M + Na]+. FAB(−):  
1253 [M − H]− 
3410, 1044 +14.8° (0.1) [37] 
37 
HR-FAB(−): 1253.6167 [M − H]− 
FAB(+): 1277 [M + Na]+. FAB(−):  
1253 [M − H]− 
3431, 1044 −8.9° (0.1) [37] 
38 FAB(+): 821 [M + Na]+ / +12.1° (1.1) [34,61] 
39 FAB(+): 659 [M + Na]+ / +9.3° (3.5) [34,61] 
40 FAB(+): 821 [M + Na]+ / +1.9° (2.6) [34,61] 
41 FAB(+): 983 [M + Na]+ / −11.6° (1.1) [34,61] 
42 FAB(+): 98 3[M + Na]+ / −1.1° (1.9) [34,61] 
43 FAB(+): 1145 [M + Na]+ / −6.2°(1.9) [34,61] 
44 FAB(+): 712 [M+2Na]+ / +53.1° (2.4) [32] 
45 
ESI-MS: 475.2 [M + H]+. HR-ESI-MS: 
475.3780 [M + H]+ 
3333, 1758, 1754, 1117, 1091, 
1033 
−0.67° (0.22) [36] 
46 HR-FAB(+): 481.3720 [M + Na]+ 
3344, 2930, 2857, 1725, 1459, 
756 
/ [62] 
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47 
ESI-MS: 475.2 [M + H]+. HR-ESI-MS: 
475.3769 [M + H]+ 
3347, 1130, 1080, 1035 +20.5° (0.27) [60] 
48 / / +53.1° (2.4) [32] 
49 
ESI-MS: 491.4 [M + H]+. HR-ESI-MS: 
491.3728 [M + H]+ 
3330, 1115, 1095, 1035 +32.3° (0.23) [60] 
50 
ESI-MS: 475.5 [M + H]+. HR-ESI-MS: 
475.3745 [M + H]+ 
3334, 1112, 1087, 1034 −1.2° (0.19) [60] 
51 
ESI-MS: 473.2 [M + H]+. HR-ESI-MS: 
473.3620 [M + H]+ 
3376, 1722, 1118, 1090, 1045 +25.5° (0.21) [60] 
52 
ESI-MS: 489.2 [M + H]+. HR-ESI-MS: 
489.3563 [M + H]+ 
3350, 1724, 1118, 1090, 1045 +26.5° (0.22) [60] 
53 
ESI-MS: 505.3 [M + H]+. HR-ESI-MS: 
505.3500 [M + H]+ 
30, 1723, 1128, 1080, 1050 +23.1° (0.27) [60] 
Table 5. Biological properties associated with the triterpenes with a focus on their potential 
chemotherapeutic applications. 
No. Activity Ref. 
1 
Antisweet activity 
Glucose uptake in rat small intestinal fragment 
Increase of serum glucose level in oral glucose-loaded rats 
Anti-hyperglycemic activity 
[31,35,38] 
[37,38] 
[46,47] 
[38] 
2 
Antisweet activity 
Glucose uptake in rat small intestinal fragment 
Increase of serum glucose level in oral glucose-loaded rats 
Anti-hyperglycemic activity 
[31,35,38] 
[37,38] 
[46,47] 
[38] 
3 
Antisweet activity 
Glucose uptake in rat small intestinal fragment 
Increase of serum glucose level in oral glucose-loaded rats 
Anti-hyperglycemic activity 
[30,31,35,38] 
[37,38] 
[46,47] 
[38] 
4 
Antisweet activity 
Glucose uptake in rat small intestinal fragment 
Increase of serum glucose level in oral glucose-loaded rats 
Anti-hyperglycemic activity 
Gut glycosidase inhibition 
[30,31,35,38] 
[37,38] 
[46,47] 
[38,65] 
[38] 
5 
Antisweet activity 
Increase of serum glucose level in oral glucose-loaded rats 
Anti-hyperglycemic activity 
Glucose uptake in rat small intestinal fragment 
[32,38] 
[46,47,65] 
[38] 
[38] 
6 Antisweet activity [32] 
7 
Antisweet activity 
Increase of serum glucose level in oral glucose-loaded rats 
[32] 
[46,47] 
10 Antisweet activity [35] 
11 Antisweet activity [35] 
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12 Antisweet activity [35] 
13 Antisweet activity [35] 
14 Antisweet activity [35] 
15 Antisweet activity [36] 
16 Antisweet activity [36] 
17 Antisweet activity [36] 
18 Antisweet activity [36] 
19 
Antisweet activity [31] 
Pharmacokinetic study: determination of gymnemagenin in rat plasma  
using HPLC-MS/MS 
[66] 
20 Antisweet activity [31] 
27 Inhibition of the 11β-hydroxysteroid dehydrogenase type 1 [63,66] 
28 Hypoglycemic and antihyperglycemic effect in rats [61] 
29 Hypoglycemic and antihyperglycemic effect in rats [61] 
30 Hypoglycemic and antihyperglycemic effect in rats [61] 
31 Hypoglycemic and antihyperglycemic effect in rats [61] 
32 Increase of serum glucose level in oral glucose-loaded rats [46,47] 
33 Increase of serum glucose level in oral glucose-loaded rats [46,47] 
34 Glucose uptake in rat small intestinal fragment [37] 
35 Glucose uptake in rat small intestinal fragment [37] 
36 Glucose uptake in rat small intestinal fragment [37] 
37 Glucose uptake in rat small intestinal fragment [37] 
39 Antisweet activity [34] 
40 
Antisweet activity 
Glucose uptake in rat small intestinal fragment 
[34] 
[46,47] 
41 Antisweet activity [34] 
42 
Antisweet activity 
Glucose uptake in rat small intestinal fragment 
[34] 
[46,47] 
43 
Antisweet activity 
Glucose uptake in rat small intestinal fragment 
[34] 
[37,47,59] 
44 
Inhibitory effects on human tumor cell lines (A549, SK-OV-3, SK-
MEL-2, and HCT15) in vitro using the sulforhodamine B (SRB) assay 
[55] 
46 
In vivo antitumor-promoting activity in mouse skin tumor [50] 
Inhibition of the tumor-promoting action of 12-O-
tetradecanoylphorbol 13-acetate 
[48,49] 
Inhibition of phospholipid synthesis by 12-O-tetradecanoylphorbol-13-
acetate  
[67] 
In vitro in human uterus cancer cells  
Anti-inflammatory activity and also to inhibit liver carcinogenesis and 
tumor growth 
[51] 
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3. Conclusions 
The market of natural substances is very attractive for its economic impact, which, on the other 
hand grows continuously. Research into new natural substances that can be used in the pharmaceutical, 
agrochemical and agro-industrial production of drugs, biopesticides and food additives has grown in 
recent years. Gymnema sylvestre is a relevant specific example of a plant very interesting for its 
numerous pharmacological properties, which include antidiabetic, anticarcinogenic, and neuroprotective 
effects, used as a medicinal plant in Asia for thousands of years. Its properties are attributed to 
triterpenoidic saponins. In light of the considerable interest generated in the chemistry and pharmacological 
properties of G. sylvestre triterpenes and their analogues, this review summarises the available 
literature on these promising bioactive natural products. The review shows the results about the 
isolation, chemistry and bioactivity of the triterpenoids oxidised at C-23, which are schematically 
presented in few tables, in particular, their isolation, distribution in different parts of the plant, and their 
NMR spectral data; their names and physico-chemical characterisation; and the biological properties 
associated with these compounds, with a focus on their potential chemotherapeutic applications. 
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